Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells

被引:33
作者
Mayo K.H. [1 ]
Van Der Schaft D.W.J. [2 ]
Griffioen A.W. [2 ]
机构
[1] Department of Biochemistry, University of Minnesota Health Sciences Center, Minneapolis, MN
[2] Tumor Angiogenesis Lab, Department of Internal Medicine and Medical Oncology, University Hospital Maastricht, Maastricht
关键词
Activity; Angiogenesis; Peptide; Structure;
D O I
10.1023/A:1016672117477
中图分类号
学科分类号
摘要
Novel β-sheet-forming peptide 33mers, βpep peptides, have been designed by using a combination approach employing basic folding principles and incorporating short sequences or proposed key residues from the β-sheet domains of interleukin-8 (IL-8), platelet factor-4 (PF4) and bactericidal/permeability increasing protein (B/PI), Since PF4 and B/PI are anti-angiogenic and IL-8 is angiogenic, the library of 30 βpep peptides was assayed for the ability to affect the growth of endothelial cells, Results indicate that five βpep peptides (βpep-2, 7, 8, 21 and 25) demonstrate greater than 50% anti-proliferative activity at 30 μg/ml, and one of those (βpep-25) is similarly active at 10 μg/ml, Insight into the mechanism of action was probed in an apoptosis assay. Anti-proliferative activity was found to be correlated with the induction of apoptosis, For example, at 100 μg/ml βpep-25 induces 85% of endothelial cells to undergo apoptosis within 2 days, These effects from βpep peptides appear to be selective for endothelial cell (EC) because normal cells (fibroblasts and leukocytes) and various tumor cells are not significantly affected at peptide concentrations used in this study, Comparison of active and inactive βpep sequences allows structure-function relationships to be deduced. Five hydrophobic residues and two lysines appear to be crucial to activity. This research contributes to the development of novel anti-angiogenic peptides.
引用
收藏
页码:45 / 51
页数:6
相关论文
共 23 条
[1]  
Griffioen A.W., Molema G., Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation, Pharmacol Rev, 52, pp. 237-268, (2000)
[2]  
Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease, Nat Med, 1, pp. 27-31, (1995)
[3]  
Gupta S.K., Hassel T., Singh J.P., A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4, Proc Natl Acad Sci USA, 92, pp. 7799-7803, (1995)
[4]  
Tolsma S.S., Volpert O.V., Good D.J., Et al., Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity, J Cell Biol, 122, pp. 497-511, (1993)
[5]  
Luster A.D., Greenberg S.M., Leder P., The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation, J Exp Med, 182, pp. 219-231, (1995)
[6]  
O'Reilly M.S., Holmgren L., Shing Y., Et al., Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung Carcinoma, Cell, 79, pp. 315-328, (1994)
[7]  
O'Reilly M.S., Boehm T., Shing Y., Et al., Endostatin: An endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, pp. 277-285, (1997)
[8]  
Pike S.E., Yao L., Jones K.D., Et al., Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth, J Exp Med, 188, pp. 2349-2356, (1998)
[9]  
Van der Schaft D.W.J., Toebes E.A.H., Haseman J.R., Et al., Bactericidal/permeability increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells, Blood, 96, pp. 176-181, (2000)
[10]  
Boehm T., Folkman J., Browder T., Oreilly M.S., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 390, pp. 404-407, (1997)